-
Product Insights
Net Present Value Model: (Deudextromethorphan hydrobromide + Quinidine sulfate)
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model (Deudextromethorphan hydrobromide + Quinidine sulfate) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (deudextromethorphan hydrobromide + quinidine sulfate)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (deudextromethorphan hydrobromide + quinidine sulfate) Drug Details AVP-786 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – deuruxolitinib phosphate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry deuruxolitinib phosphate Drug Details Deuruxolitinib phosphate (CTP-543, Deuterated Ruxolitinib) is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PCS-499
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry PCS-499 Drug Details PCS-499 (deuterated S-lisofylline, CTP-499) is under development for the treatment of...